| P2093 | author name string | Rengaswamy Sankaranarayanan | |
| P2860 | cites work | Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review | Q28294064 |
| | Testing previous model predictions against new data on human papillomavirus vaccination program outcomes | Q30764433 |
| | Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types | Q33682928 |
| | Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial | Q34342056 |
| | Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine | Q35268615 |
| | Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study | Q35918842 |
| | A review of clinical trials of human papillomavirus prophylactic vaccines | Q36259403 |
| | Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India | Q36785915 |
| | Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study | Q36977720 |
| | Updating the natural history of human papillomavirus and anogenital cancers | Q36979148 |
| | Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study | Q37137085 |
| | Integration of comprehensive women's health programmes into health systems: cervical cancer prevention, care and control in Rwanda | Q37214456 |
| | Model for assessing human papillomavirus vaccination strategies | Q37302509 |
| | The Australian experience with the human papillomavirus vaccine | Q38177897 |
| | Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study | Q39107868 |
| | Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries | Q39438673 |
| | Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women | Q42236236 |
| | Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months | Q42248061 |
| | Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial | Q42257816 |
| | Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico | Q45226669 |
| P304 | page(s) | S33-5 | |
| P577 | publication date | 2015-02-25 | |
| P1433 | published in | International Journal of Gynecology and Obstetrics | Q15746544 |
| P1476 | title | HPV vaccination: The most pragmatic cervical cancer primary prevention strategy. | |
| P478 | volume | 131 Suppl 1 | |